Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging

BACKGROUND: The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, the pharmacological evidence has not been fully revealed. RESULTS: Erlotinib distribution in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Meiko, Hayashi, Mitsuhiro, Mizutani, Yu, Takenaka, Kei, Imamura, Yoshinori, Chayahara, Naoko, Toyoda, Masanori, Kiyota, Naomi, Mukohara, Toru, Aikawa, Hiroaki, Fujiwara, Yasuhiro, Hamada, Akinobu, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915091/
https://www.ncbi.nlm.nih.gov/pubmed/29719624
http://dx.doi.org/10.18632/oncotarget.24928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915091/
https://www.ncbi.nlm.nih.gov/pubmed/29719624
http://dx.doi.org/10.18632/oncotarget.24928

Ejemplares similares